- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00976404
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir (EraMune02)
September 10, 2014 updated by: Robert L. Murphy
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation.
The hypothesis is that eradication is possible only if very potent antiretroviral drugs are delivered in conjunction with an immunomodulatory agent that simultaneously attack the viral reservoirs.
Study Overview
Status
Completed
Conditions
Detailed Description
The objective of this study is to measure the impact of immunomodulation plus treatment intensification on the HIV reservoir in HIV-infected patients who have viral suppression on combination antiretroviral therapy.
Treatment regimens first will be intensified by the addition of raltegravir and maraviroc for 8 week followed by immunomodulation with the NIH HIV-rAd5 vaccine plus DNA prime-boost for 24 weeks.
The primary endpoint is measurement of change in peripheral cellular HIV DNA.
A decrease of 0.5 log is considered significant.
A secondary endpoints include change in HIV DNA in the rectal mucosa, immunologic changes in the peripheral blood and safety.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- University of California San Francisco
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
New York
-
New York, New York, United States, 10011
- Cornell University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-1 infection
- At least 3 years of ART without interruption (less than one month cumulative)
- ART regimen unchanged in the 3 months prior to screening
- One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral load (RNA) documented per year thereafter
- HIV plasma viral load (RNA) ≤ 500 copies/mL at least 3 years prior to entry, and HIV plasma viral load < 500 copies/mL for >90% of the measures thereafter
- HIV plasma viral load (RNA) below the limit of detection for all values within the past year (one virologic blip allowed)
- HIV plasma viral load below the limit of detection within 60 days of entry
- CD4+ count ≥ 350 cells/mm3 within 60 days of entry
- Proviral DNA ≥10 and ≤1000 copies/106 PBMCs within 75 days of entry
- Adeno5 neutralizing antibody titers of 250 or less within 75 days of entry
- Hemoglobin ≥ 10 g/dL within 60 days of entry
- Platelets ≥ 100,000 per microliter within 60 days of entry
- Hepatic transaminases (ALT and AST) ≤ 2.5 x ULN within 60 days of entry
- Creatinine clearance > 50 mL/min by the Cockcroft-Gault equation within 60 days of entry
Exclusion Criteria:
- Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc)
- Pregnancy
- Inability or unwillingness to provide informed consent
- HBsAg positive
- HCV antibody positive or HCV RNA detectable
- Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such as intensification or toxicity switches is allowed.
- Immunologic therapeutic intervention (e.g. IL-2) within the past year
- Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
- Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy)
- Co-morbid condition with an expected survival of less than 12 months
- History of hypersensitivity to vaccination
- History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto's thyroiditis
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Maraviroc + raltegravir intensification
ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
|
raltegravir 400 mg PO BID for 56 weeks
Other Names:
maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Other Names:
|
Experimental: Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine
ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
|
raltegravir 400 mg PO BID for 56 weeks
Other Names:
maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Other Names:
4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in HIV DNA in PBMCs at Week 56
Time Frame: 56 weeks
|
56 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in HIV DNA in Rectal Tissue at Week 56
Time Frame: Week 56
|
Week 56
|
|
Change From Baseline in CD4+ T Cell Count at Week 56
Time Frame: Week 56
|
Week 56
|
|
HIV Specific T-cell Response to Env
Time Frame: 36 weeks
|
HIV-specific immunity: Interferon gamma ELISpot response to Env (clades A) at week 36 (one month after rAd5 boosting)
|
36 weeks
|
Serious Adverse Events Attributed to Study Treatments
Time Frame: 56 weeks
|
Grade 3 or 4 serious adverse events related to study treatments (raltegravir, maraviroc, or HIV-recombinant Ad5-based vaccine)
|
56 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Robert Murphy, MD, Northwestern University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
September 9, 2009
First Submitted That Met QC Criteria
September 11, 2009
First Posted (Estimate)
September 14, 2009
Study Record Updates
Last Update Posted (Estimate)
September 12, 2014
Last Update Submitted That Met QC Criteria
September 10, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- HIV Fusion Inhibitors
- Viral Fusion Protein Inhibitors
- CCR5 Receptor Antagonists
- Raltegravir Potassium
- Maraviroc
Other Study ID Numbers
- EraMune02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Northwestern UniversityPfizer; Tibotec, IncCompletedHIV Infections | HIV-1 InfectionUnited States
Clinical Trials on ART intensification (raltegravir)
-
Objectif Recherche Vaccins SIDAMerck Sharp & Dohme LLC; Pfizer; Cytheris SACompletedHIV-1 InfectionUnited Kingdom, France, Italy, Spain
-
Sante Diabete MaliFrench Development Agency; Société Francophone du Diabète; Centre hospitalo-universiaire...Completed
-
University of Erlangen-Nürnberg Medical SchoolUnknown
-
Harvard School of Public Health (HSPH)Addis Continental Institute of Public Health; The International Livestock Research... and other collaboratorsCompletedHealth Behavior | Dietary ModificationEthiopia
-
Brigham and Women's HospitalRobert Wood Johnson FoundationUnknownHypertensionUnited States
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States, Canada
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Merck Sharp & Dohme LLCCompleted
-
Kaiser Franz Josef HospitalWithdrawnPlatelet Dysfunction Due to Drugs | Coronary ArteriosclerosesAustria
-
Laboratoires NEGMAUnknown
-
Foundation for Atlanta Veterans Education and Research...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory... and other collaboratorsRecruitingType 2 DiabetesUnited States